콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

N2260

Supelco

D(−)-Norgestrel

analytical standard

동의어(들):

13β-Ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one, 17α-Ethynyl-18-homo-19-nor-testosterone, 18,19-Dinor-13β-ethyl-17β-hydroxy-4-pregnen-20-yn-3-one, 18,19-Dinor-4-pregnen-20-yn-3-one, Levonorgestrel

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C21H28O2
CAS Number:
Molecular Weight:
312.45
EC Number:
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24

Grade

analytical standard

Quality Level

분석

≥99%

기술

HPLC: suitable
gas chromatography (GC): suitable

응용 분야

forensics and toxicology
veterinary

형식

neat

저장 온도

2-8°C

SMILES string

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChI key

WWYNJERNGUHSAO-XUDSTZEESA-N

유전자 정보

human ... PGR(5241)
rat ... Ar(24208)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

관련 카테고리

일반 설명

D(−)-Norgestrel is a hormonal medication and a contraceptive used by women.

애플리케이션

D(−)-Norgestrel may be used as a reference standard for the analysis of the analyte in human plasma using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS).
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

애플리케이션

픽토그램

Health hazard

신호어

Danger

유해 및 위험 성명서

Hazard Classifications

Carc. 2 - Lact. - Repr. 1A

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

개인 보호 장비

dust mask type N95 (US), Eyeshields, Gloves


Choose from one of the most recent versions:

시험 성적서(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Analytical Methods for Therapeutic Drug Monitoring and Toxicology (2011)
Alice W Y Wong et al.
Obstetrics and gynecology, 121(5), 943-950 (2013-05-03)
To estimate the rate of endometrial pathology with the prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen. This was a randomized contro-lled trial of 129 Chinese women who attended a university hospital in Hong
Abbey B Berenson et al.
Obstetrics and gynecology, 121(5), 951-958 (2013-05-03)
Many U.S. health care providers remain reluctant to prescribe intrauterine devices (IUDs) to teenagers as a result of concerns about serious complications. This study examined whether 15-19-year-old IUD users were more likely to experience complications, failure, or early discontinuation than
Anita Nelson et al.
Obstetrics and gynecology, 122(6), 1205-1213 (2013-11-19)
To evaluate the efficacy and safety of two low-dose levonorgestrel intrauterine contraceptive systems. Nulliparous and parous women aged 18-35 years with regular menstrual cycles (21-35 days) requesting contraception were randomized to 3 years of treatment with one of two levonorgestrel
Satu Heliövaara-Peippo et al.
American journal of obstetrics and gynecology, 209(6), 535-535 (2013-09-04)
Menorrhagia is a common problem impairing the quality of life (QOL) of many women. Both levonorgestrel-releasing intrauterine system (LNG-IUS) and hysterectomy are effective treatment modalities but no long-term comparative studies of QOL and costs exist. The objective of this study

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.